Non-small cell lung cancer

Description: 
Available tests: Fluorescence in situ hybridisation analysis of FFPE tissue sections for: ALK t(2p23;) rearrangement; ROS1 t(6q22;) rearrangement; MET (7q31) copy number/ratio; RET t(10q11;) rearrangement
Clinical details: 
The determination of ALK status in patients with lung cancer is critical in the identification of patients eligible for ALK inhibitor therapy. Patients with ROS1 rearrangement have also been shown to be sensitive to the ALK inhibitor crizotininb, MET amplification may contribute to acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI's), and may be a target for MET inhibitors. Patients showing rearrangement of RET have been shown to benefit from treatment with RET tyrosine kinase inhibitors.
Synonyms or keywords: 
ALK, ROS1, MET, RET, crizotininb, Xalkori, lung cancer, non-small cell lung cancer, adenocarcinoma, NSCLC
Department: 
Genetics Department
Location: 
Guy's Hospital
Sample type and Volume required: 
FFPE tissue sections – 3-4µm sections on unstained Apes slides with appropriate IHC/H&E slide for correlation
Turnaround time: 
Current service turnaround times: Urgent 2-7 calendar days; Non-urgent 5-10 calendar days; National targets: Urgent samples 95% reported within 14 days; Non-urgent 95% reprted within 21 days
Criteria for acceptance / rejections of sample
Contacts:
Oncology Cytogenetics Laboratory at Guy's Hospital
020 7188 1713
viapath.OncologyDutyScientist@nhs.net
Genetics Department
Tower Wing - 5th Floor
Guy's Hospital
Great Maze Pond
London SE1 9RT

For clinical advice or interpretation of results, please contact the laboratory in the first instance.
Laboratory: 
Oncology Cytogenetics at Guy's

Print as a PDF

Last updated: 28/09/2021